International Clinical Trial: A multicenter, randomized, double-blind, placebo-controlled Phase II clinical study evaluating the efficacy and safety of CMS-D001 in patients with moderate to severe atopic dermatitis

Geneva, March 20 -- International Clinical Trials Registry received information related to the study (ChiCTR2600119266) titled 'A multicenter, randomized, double-blind, placebo-controlled Phase II clinical study evaluating the efficacy and safety of CMS-D001 in patients with moderate to severe atopic dermatitis' on Feb. 25.

Study Type: Interventional study

Study Design: Parallel

Primary Sponsor: China-Japan Friendship Hospital

Condition: Atopic dermatitis

Intervention: 50mg QD group:Take the medication on an empty stomach, once a day, for a duration of 12 weeks. 100mg QD group:Take the medication on an empty stomach, once a day, for a duration of 12 weeks. 200mg QD group:Take the medication on an empty stomach, once a day, fo...